Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson Post author:Sam Post published:February 8, 2018 Post category:BioPharma Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace You Might Also Like <b>SerImmune</b> Raises $8M To Map The Human Antibody Repertoire June 19, 2017 Shire CFO Quits for Boston-Based Microbiome Startup August 21, 2017 Clarus Ventures Wants To Pick Up The Tab For Big Pharma's R&D With New $910 Million Fund July 17, 2017
Clarus Ventures Wants To Pick Up The Tab For Big Pharma's R&D With New $910 Million Fund July 17, 2017
